Mitochondrial targeting of growth suppressor protein DLC2 through the START domain

Saved in:
Bibliographic Details
Title: Mitochondrial targeting of growth suppressor protein DLC2 through the START domain
Authors: Ng, David Chi-Heng1, Chan, Shing-Fai1, Kok, Kin Hang1, Yam, Judy Wai Ping1,2, Ching, Yick-Pang1,2, Ng, Irene Oi-lin2, Jin, Dong-Yan1 dyjin@hkucc.hku.hk
Source: FEBS Letters. Jan2006, Vol. 580 Issue 1, p191-198. 8p.
Subjects: Tumor suppressor proteins, Tumor suppressor genes, Liver cancer, Blood plasma
Abstract: Abstract: Deleted in liver cancer 2 (DLC2) is a candidate tumor suppressor frequently found to be deleted in hepatocellular carcinoma. In this study, we determined the subcellular localization of DLC2. Co-localization and biochemical fractionation studies revealed that DLC2 localized to mitochondria. In addition, the DLC2-containing cytoplasmic speckles were in proximity to lipid droplets. A DLC2 mutant containing the steroidogenic acute regulatory protein-related lipid transfer (START) domain only showed a localization pattern identical to that of DLC2. Taken together, we have provided the first evidence for mitochondrial localization of DLC2 through the START domain. These findings might have implications in liver physiology and carcinogenesis. [Copyright &y& Elsevier]
Copyright of FEBS Letters is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Description
Abstract:Abstract: Deleted in liver cancer 2 (DLC2) is a candidate tumor suppressor frequently found to be deleted in hepatocellular carcinoma. In this study, we determined the subcellular localization of DLC2. Co-localization and biochemical fractionation studies revealed that DLC2 localized to mitochondria. In addition, the DLC2-containing cytoplasmic speckles were in proximity to lipid droplets. A DLC2 mutant containing the steroidogenic acute regulatory protein-related lipid transfer (START) domain only showed a localization pattern identical to that of DLC2. Taken together, we have provided the first evidence for mitochondrial localization of DLC2 through the START domain. These findings might have implications in liver physiology and carcinogenesis. [Copyright &y& Elsevier]
ISSN:00145793
DOI:10.1016/j.febslet.2005.11.073